Publicaciones en las que colabora con José María Ruiz Moreno (30)

2024

  1. Assessing the economic burden of vision loss and irreversible legal blindness in Spain (2021–2030): a societal perspective

    Health Economics Review, Vol. 14, Núm. 1

  2. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials

    Ophthalmology, Vol. 131, Núm. 6, pp. 708-723

  3. Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration

    Ophthalmology Retina, Vol. 8, Núm. 4, pp. 350-359

  4. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2

    Ophthalmology, Vol. 131, Núm. 8, pp. 914-926

2023

  1. A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration

    Ophthalmology, Vol. 130, Núm. 6, pp. 588-597

  2. Effectiveness and safety of fluocinolone acetonide intravitreal implant in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT): a prospective, non-randomized, and multicenter study

    International Ophthalmology, Vol. 43, Núm. 12, pp. 4639-4649

  3. Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial

    Japanese Journal of Ophthalmology, Vol. 67, Núm. 3, pp. 264-279

2022

  1. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

    The Lancet, Vol. 399, Núm. 10326, pp. 729-740

  2. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

    The Lancet, Vol. 399, Núm. 10326, pp. 741-755

2021

  1. Challenges in diabetic macular edema management: An expert consensus report

    Clinical Ophthalmology, Vol. 15, pp. 3183-3195

2020

  1. A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study

    PharmacoEconomics - Open, Vol. 4, Núm. 4, pp. 615-624

  2. Bimonthly, treat-and-extend and as-needed ranibizumab in naïve neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study

    Acta Ophthalmologica, Vol. 98, Núm. 7, pp. e820-e829

  3. Genetic and environmental factors related to the development of myopic maculopathy in Spanish patients

    PloS one, Vol. 15, Núm. 7, pp. e0236071

  4. Use of intravitreal dexamethasone implants in the treatment of diabetic macular edema: Expert recommendations using a Delphi approach

    European Journal of Ophthalmology, Vol. 30, Núm. 5, pp. 1042-1052

2019

  1. Management of Wet Age-Related Macular Degeneration in Spain: Challenges for Treat and Extend Implementation in Routine Clinical Practice

    Journal of Ophthalmology, Vol. 2019

  2. Myopic maculopathy: Current status and proposal for a new classification and grading system (ATN)

    Progress in Retinal and Eye Research, Vol. 69, pp. 80-115

2018

  1. Clinical decision-making when treating diabetic macular edema patients with dexamethasone intravitreal implants

    Ophthalmologica, Vol. 240, Núm. 2, pp. 61-72

  2. Degeneración macular asociada a la edad (DMAE) atrófica

    s.n.

2017

  1. Early and intermediate age-related macular degeneration: Update and clinical review

    Clinical Interventions in Aging, Vol. 12, pp. 1579-1587

  2. Prevalence of Vitreoretinal Interface Abnormalities on Spectral-Domain OCT in Healthy Participants over 45 Years of Age

    Ophthalmology Retina